In a preemptive strike against the potential commodification of deeply personal genomic information, a coalition of twenty-seven states, alongside the District of Columbia, has initiated legal proceedings against 23andMe, the embattled genetic testing purveyor, endeavouring to forestall the unconsented transfer of proprietary genetic profiles in the wake of a proposed acquisition by a biotechnology conglomerate; this juridical intervention, spearheaded by Oregon's Attorney General Dan Rayfield, pivots on the contention that the granular dataset at stake, encompassing biological matrices, deconstructed DNA sequences, phenotypic predispositions, and comprehensive medical chronologies, constitutes an inviolable informational corpus, the alienation of which necessitates the explicit, informed acquiescence of each data-contributing individual, particularly given 23andMe's post-IPO financial precarity, exemplified by draconian workforce reductions and Chapter 11 recourse, notwithstanding assurances from prospective acquirer Regeneron Pharmaceuticals regarding adherence to extant privacy protocols and the appointment of an independent ombudsman to scrutinise the ramifications of the impending transaction.